The need for urogenital tract monitoring in COVID-19

Nat Rev Urol. 2020 Jun;17(6):314-315. doi: 10.1038/s41585-020-0319-7.

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, which invades a cell through binding to the ACE2 receptor and TMPRSS2 priming. Patients with severe disease predominantly present with pneumonia-related symptoms. However, evidence suggests that COVID-19 infection also has implications for the urogenital tract. Thus, urogenital organs should be considered when treating COVID-19.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury / diagnosis*
  • Acute Kidney Injury / metabolism
  • Acute Kidney Injury / virology*
  • Angiotensin-Converting Enzyme 2
  • Betacoronavirus* / metabolism
  • COVID-19
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / metabolism
  • Humans
  • Male
  • Pandemics
  • Peptidyl-Dipeptidase A / metabolism
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / metabolism
  • SARS-CoV-2
  • Testis / metabolism
  • Testis / pathology
  • Testis / virology*
  • Urogenital System / metabolism
  • Urogenital System / pathology
  • Urogenital System / virology*

Substances

  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2